Study at a glance
How does the body break down vitamin D?
This review brings together enzyme experiments, animal studies and human genetics to explain how the body breaks down vitamin D compounds. It focuses on CYP24A1, an enzyme that acts on both 25-hydroxyvitamin D, the starting compound for activation, and active vitamin D itself. Breakdown happens through several chemical steps and can follow different routes.
How does breakdown limit vitamin D activity?
Active vitamin D can cause cells to make more CYP24A1. The enzyme then helps remove active vitamin D and its starting compound, limiting further activity. In mice without CYP24A1, the time taken for the amount of active vitamin D in blood to fall by half increased from about 6 to 60 hours. Rare inherited loss of enzyme function in people is linked to high blood calcium.
Does breaking down vitamin D always make it inactive?
Changing one building block of the enzyme reversed the chemical route it usually follows in an experiment. Different species can also favour different routes. Some compounds formed during breakdown may still affect the body. Animal findings suggest possible roles in bone healing, but it remains unclear whether these compounds have a separate action and how it works. Another enzyme, CYP3A4, can break down vitamin D compounds in some tissues. Its importance at ordinary concentrations is uncertain.
Can vitamin D breakdown findings in mice be applied to people?
The timing measured in mice cannot simply be applied to people. Severe inherited disease does not show that ordinary differences between people have the same cause. Hormones that control vitamin D breakdown in the kidneys may not control it the same way in every tissue. Overall, CYP24A1 helps control how quickly vitamin D compounds change and how long their effects last. It does not make every product immediately inactive.
Read the full article below ↓Vitamin D signalling is controlled not only by how much active hormone is produced, but also by how quickly precursor and active metabolites are transformed after they enter a cell. Jones, Prosser and Kaufmann’s thematic review places CYP24A1 at the centre of that catabolic system. The enzyme is not a one-step “off switch.” It is a mitochondrial cytochrome P450 that can act on both 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D], initiate different oxidation routes, carry out repeated side-chain reactions and participate in feedback that limits active-hormone exposure.
The source also shows why the word “inactivation” needs qualification. Some intermediate and alternative products retain biological activity, and CYP24A1 is not the only catabolic enzyme in every tissue. CYP3A4 provides an additional route in liver and intestine. The scientific question is therefore how intracellular degradation and feedback regulate vitamin D exposure, including the chemistry, structural determinants, physiological evidence, alternative pathways and limits of a simple activation-versus-inactivation model.
CYP24A1 is a mitochondrial, electron-transfer-dependent enzyme
CYP24A1 belongs to the mitochondrial class of vitamin D-related cytochrome P450 enzymes. Its catalytic activity depends on electron transfer through ferredoxin reductase and ferredoxin to the CYP haem centre. This biochemical architecture matters because CYP24A1 is not simply a binding protein or a transcriptional marker of vitamin D response; it is an enzyme whose catalytic cycle requires substrate access, redox partners and correct positioning of the vitamin D side chain above the haem-bound reactive oxygen intermediate.
The enzyme accepts both 25(OH)D and 1,25(OH)2D. Catabolism can therefore operate before activation, by reducing precursor available to CYP27B1, and after activation, by shortening the lifetime of the active VDR ligand. That dual-substrate role makes CYP24A1 a control point on both sides of the active-hormone pool.
One CYP24A1 molecule can drive multistep C24 and C23 pathways
Recombinant-enzyme work established that CYP24A1 is capable of multiple sequential hydroxylations rather than one isolated 24-hydroxylation. In the C24 pathway, repeated side-chain oxidation can carry 1,25(OH)2D through a sequence of metabolites toward calcitroic acid, a water-soluble biliary catabolite. A distinct C23-initiated pathway can progress toward a 26,23-lactone. The enzyme also acts on 25(OH)D and on vitamin D2 metabolites, although the exact product series differs.
The order of products and the existence of two routes are important mechanistically. “CYP24A1 activity” does not identify one chemical event or one downstream molecule. The same enzyme can commit substrate to different oxidation sequences, and the physiological meaning depends partly on which pathway is favoured.
Species and active-site structure change product routing
The review develops unusually detailed structure-function evidence for CYP24A1 regioselectivity. Across species, residue 326 is a major determinant of whether C24 or C23 oxidation predominates. Most orthologues with alanine at this position favour the C24 route, whereas glycine is associated with greater C23 hydroxylation. Opossum CYP24A1, for example, is strongly C23-directed.
A single human Ala326Gly substitution changed the C24:C23 product ratio from 8.1:1 to 1:8.3. This is not a minor quantitative shift: one amino-acid substitution reversed the preferred metabolic route. Structural modelling explains why. Residue 326 sits directly above the haem near the substrate side chain; replacing alanine with the smaller glycine creates extra space, allowing the side chain to move deeper and position C23 rather than C24 for oxidation.
Other residues also influence binding and routing. The review discusses Ile131, Leu148, Met246, Val391 and sites within the substrate-access region. In rat CYP24A1, mutations at Thr416 and Ile500 moved a reported C24:C23 ratio from roughly 100:1 to about 12.5:1 and 6.3:1, respectively. Mutations facing into the substrate-binding cavity impaired binding more strongly than mutations facing away from it. Together with the rat CYP24A1 crystal structure, these experiments connect amino-acid architecture, substrate positioning and product identity rather than treating regioselectivity as a descriptive species difference.
Structural evidence changes how catabolism should be interpreted
The structure-function data show that downstream vitamin D chemistry is not predetermined by the presence of CYP24A1 alone. Product routing depends on how the substrate occupies the active site, and small changes in the binding pocket can alter the balance between pathways. This gives a molecular basis for species differences and explains why results from one orthologue cannot always be transferred numerically to another.
It also provides a broader physiological lesson: catabolic capacity has qualitative as well as quantitative dimensions. Two cells with similar CYP24A1 abundance could, in principle, generate different metabolite profiles if enzyme sequence, substrate availability or competing pathways differ. The source does not demonstrate that such sequence variation routinely drives human tissue differences, so that implication must remain bounded to the structural evidence.
CYP24A1 is built into VDR-linked negative feedback
CYP24A1 is expressed in many VDR-containing target tissues, including kidney, bone and intestine, and is strongly inducible by VDR agonists. Cloning and promoter analysis identified vitamin-D-responsive regulatory elements, while later chromatin-immunoprecipitation work showed that regulation is more complex than a single promoter site, with multiple VDR-binding regions and downstream regulatory elements contributing.
This creates a direct feedback architecture. Rising intracellular 1,25(OH)2D activates VDR-dependent transcription and can increase CYP24A1 expression; the induced enzyme then metabolises 1,25(OH)2D and can also reduce 25(OH)D available for future activation. Signalling therefore increases the cell’s capacity to constrain subsequent signalling. The feedback is metabolically coherent rather than a separate downstream response.
The review also cautions against reducing this regulation to one universal genomic switch. The exact regulatory architecture differs by tissue, and later work on downstream elements reinforces that CYP24A1 induction is integrated with cell-specific chromatin and endocrine context.
Cyp24a1-null mice quantify the effect on active-hormone persistence
Knockout physiology provides one of the strongest quantitative demonstrations of CYP24A1 function. In Cyp24a1-null mice, clearance of 1,25(OH)2D is dramatically reduced and the plasma half-life of the hormone rises approximately ten-fold, from about 6 hours to about 60 hours. This result gives scale to a statement that would otherwise remain qualitative: CYP24A1 can be a major determinant of how long active vitamin D remains available in vivo.
The knockout phenotype also includes marked disturbances of bone mineralisation. Jones and colleagues note that the intramembranous-bone lesion is absent in double Cyp24a1/Vdr-null mice, supporting the interpretation that excessive VDR-mediated signalling, rather than simple absence of one 24-hydroxylated product, contributes to that phenotype. The model remains specific, but it shows that failed catabolism can alter signalling consequences as well as metabolite concentrations.
Human CYP24A1 loss-of-function links failed clearance to hypercalcaemia
Human genetics supplies a complementary causal line. Jones and colleagues describe loss-of-function mutations in CYP24A1 underlying idiopathic infantile hypercalcaemia in multiple families. This genetic evidence links impaired vitamin D catabolism directly to a hypercalcaemic disease phenotype and reinforces the physiological importance of the enzyme.
These disorders show what happens when clearance capacity is lost, but they should not be used as a template for ordinary inter-individual variation. Severe monogenic disease demonstrates physiological necessity; it does not establish that common nonspecific symptoms are usually caused by clinically meaningful CYP24A1 dysfunction.
Catabolism does not make every product biologically silent
The C24 pathway ultimately reaches calcitroic acid, but Jones and colleagues caution against assuming that every 24-hydroxylated product is immediately biologically irrelevant. Experimental administration of 24-hydroxylated metabolites accelerated fracture healing in animal models, and related work in Cyp24a1-null mice kept open the possibility of a distinct biological action.
Those observations do not reverse CYP24A1’s established catabolic role, and Jones expressly treats the proposed anabolic mechanism as unresolved: acceptance of a unique role for 24,25(OH)2D in bone healing depends on demonstrating a receptor and its signalling pathway. The correct boundary is therefore that CYP24A1-mediated transformation generally attenuates and terminates vitamin D signalling, while reported effects of some 24-hydroxylated metabolites prevent an assertion of immediate universal biological silence.
CYP3A4 provides an alternative catabolic route in selected tissues
CYP24A1 is the key vitamin D catabolic enzyme, but Jones and colleagues also discuss the nonspecific microsomal enzyme CYP3A4 in liver and intestine. CYP3A4 can hydroxylate vitamin D compounds, including 1,25(OH)2D, at several positions and is inducible by 1,25(OH)2D in intestinal cells. Its broad substrate range distinguishes it from the dedicated mitochondrial CYP24A1 system.
The source places a strong boundary around that alternative route. Reported CYP3A4 activity toward vitamin D compounds has micromolar substrate constants, which makes ordinary physiological relevance uncertain even though pharmacological relevance remains plausible. Human intestinal microsomes and recombinant CYP3A4 can degrade vitamin D compounds, with evidence for differential handling of vitamin D2 metabolites, so the route matters most clearly at high concentrations and in selected tissues or exposure settings.
CYP3A4 therefore prevents an absolute claim that only CYP24A1 can metabolise vitamin D compounds, but it should not be promoted to an equally important physiological clearance pathway on this source. Jones concludes that its main relevance may be in inactivation at high concentrations, preserving a distinction between biochemical capability and established ordinary physiological contribution.
Mineral hormones regulate the catabolic arm as part of reciprocal feedback
CYP24A1 induction by active vitamin D does not operate in isolation from mineral-hormone control. In kidney, parathyroid hormone (PTH) generally shifts the system toward greater calcitriol availability. The review describes evidence that PTH can attenuate 1,25(OH)2D-driven CYP24A1 expression, including post-transcriptional effects that destabilise CYP24A1 mRNA and increase its degradation. This complements PTH stimulation of CYP27B1 and helps move renal metabolism toward activation rather than clearance when calcium demand is high.
Fibroblast growth factor 23 (FGF23) pushes the system in the opposite direction. Rising phosphate stimulates FGF23, which reduces renal phosphate reabsorption, suppresses CYP27B1 and promotes renal CYP24A1 expression. The two hydroxylases therefore respond reciprocally to a signal that lowers calcitriol availability while also promoting phosphaturia.
These interactions matter because they place cellular catabolism inside whole-system feedback. A change in CYP24A1 expression is not merely a local chemical event; in kidney it is coordinated with the enzyme that makes calcitriol and with endocrine signals responding to calcium and phosphate balance. At the same time, this renal programme should not be copied unchanged onto every target tissue, where VDR-linked induction and alternative local signals may dominate.
Activation and degradation form a regulated metabolic balance
CYP24A1 is best understood together with CYP27B1. CYP27B1 raises cellular 1,25(OH)2D by activating 25(OH)D; CYP24A1 can reduce precursor before activation and shorten active-hormone exposure after activation. VDR activation can then induce CYP24A1, feeding information from signalling back into metabolism. In selected tissues, CYP3A4 adds another removal route.
This balance means that neither total substrate concentration nor expression of one enzyme defines the intracellular state. The relevant exposure depends on substrate entry, CYP27B1 activity, CYP24A1 abundance and induction, alternative enzymes, product routing and the biological properties of intermediates. The system behaves as competing fluxes rather than as a linear one-way pathway.
What the source establishes and where the boundary remains
The evidence supports CYP24A1 as a major physiological regulator of vitamin D metabolite clearance and a central component of VDR-linked negative feedback. Multistep chemistry, structural mutagenesis, crystal-structure interpretation, knockout physiology and human genetics converge on that conclusion. The approximately 6-to-60-hour half-life change in Cyp24a1-null mice supplies quantitative scale; the Ala326Gly reversal from 8.1:1 to 1:8.3 supplies a striking structure-function demonstration; and alternative CYP3A4 metabolism prevents an unsupported claim of exclusivity.
The same evidence also sets clear limits. Product identity and pathway preference can be species dependent. Some downstream metabolites retain biological activity. CYP24A1 is not the only relevant catabolic enzyme in every tissue. Renal and target-cell feedback architecture should not be assumed identical. The strongest conclusion is therefore more precise than “CYP24A1 switches vitamin D off”: CYP24A1 controls the rate, route and duration of vitamin D metabolite turnover within a feedback-regulated network, but degradation is chemically plural and biologically more nuanced than immediate universal inactivation.
This feedback-and-catabolism evidence develops the termination side of Vitamin D Metabolism at the Cellular Level. Vitamin D Clearance and Degradation follows the removal pathways in more detail, while Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) places degradation opposite activation.
Primary source
Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research. 2014;55(1):13 to 31. Read the full paper.
The Study Summary condenses the multistep catabolic chemistry, feedback evidence and key limitations.
Related reading
Adherence to the dietary index for gut microbiota and the 5-year incidence of metabolic dysfunction-associated steatotic liver disease in Iranian adults: a prospective cohort study
The five-year incidence of MASLD was evaluated using multivariable logistic regression models, and associations were expressed as odds ratios (ORs) with 95% confidence intervals (CIs).
Original paper ↗Read more →Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins
Here, we investigated the association between DI-GM, a novel metric reflecting diet-microbiota interactions, MAFLD, and liver fibrosis, with a focus on the mediating role of vitamins.
Original paper ↗Read more →Calcitriol attenuates diethylnitrosamine-induced hepatic fibrosis in rats by reducing oxidative stress and fibrogenic mediators
This study investigated the effects of calcitriol on oxidative stress, inflammation, and fibrogenesis in DEN-induced liver fibrosis rat model.
Original paper ↗Read more →Calcitriol-Mediated Hypercalcemia Due to Liver Metastases in a Patient With Primary Pancreatic Neuroendocrine Tumor
Hypercalcemia is most commonly associated with primary hyperparathyroidism or malignancy in the setting of elevated parathyroid hormone-related protein or bone metastases.
Original paper ↗Read more →Colon-Specific Gut Microbiome Remodelling Is Associated with Host Metabolism in Paracetamol-Induced Liver Injury in Rats
The gut and liver are functionally coupled along the gut: liver axis, yet most studies treat the intestine as a single compartment and sample feces alone.
Original paper ↗Read more →COVID-19 Vaccines for Adults and Children with Autoimmune Gut or Liver Disease
The SARS-CoV-2 pandemic raised many challenges for all patients with chronic conditions and those with autoimmune diseases, both adults and children.
Original paper ↗Read more →Gut-Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis
This study aimed to systematically reveal these dynamics and explore the link between gut microbiota and metabolism in a spontaneous reversal model.
Original paper ↗Read more →Interaction Between Liver Metabolism and Gut Short-Chain Fatty Acids via Liver-Gut Axis Affects Body Weight in Lambs
Thus, we examined the jejunal microbiota, fermentation parameters, digestive enzymes, morphology, and liver metabolic profiles in different growth development lambs to investigate the liver: gut axis’s role in their development.
Original paper ↗Read more →Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship?
We evaluated changes in the gut microbiota in NAFLD adolescents compared with healthy controls.
Original paper ↗Read more →The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism
The present study evaluated the efficacy of calcitriol treatment in NAFLD patients with regard to the vitamin D receptor (VDR) genotypes of FokI polymorphism.
Original paper ↗Read more →Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models
On the other hand, disorder of gut microbiota, namely dysbiosis, is known to cause MetS and NAFLD.
Original paper ↗Read more →Association of longitudinal serum 25-hydroxyvitamin D trajectories with subsequent liver stiffness increase in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
We evaluated the associations of longitudinal 25(OH)D trajectories with subsequent liver stiffness measurement (LSM) increases in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.
Original paper ↗Read more →Correlation of Vitamin 25(OH)D, Liver Enzymes, Potassium, and Oxidative Stress Markers with Lipid Profile and Atheromatic Index: A Pilot Study
This study aims to investigate the correlation of lipid profile and atheromatic index TC/HDL with several biomarkers and oxidative stress parameters.
Original paper ↗Read more →Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients
The objective of this study is to retrospectively probe the association between the 25-hydroxyvitamin D (25-(OH)D) and NAFLD in type 2 diabetic patients.
Original paper ↗Read more →Disrupted Vitamin D Metabolism in Hepatocellular Carcinoma: Free and Bioavailable 25(OH)D as Novel Biomarkers of Hepatic Reserve and Clinical Risk
Correlations with Child: Pugh score, Barcelona Clinic Liver Cancer (BCLC) stage, and disease aetiology were evaluated.
Original paper ↗Read more →Higher Serum 25-Hydroxyvitamin D Is Associated with Lower All-Cause and Cardiovascular Mortality among US Adults with Nonalcoholic Fatty Liver Disease
Aims: We aimed to assess the association between serum 25-hydroxyvitamin D (25(OH)D) levels with all-cause and cardiovascular mortality in patients with nonalcoholic fatty liver disease (NAFLD).
Original paper ↗Read more →Liver Graft Pathology and Low Serum 25-Hydroxyvitamin D after Living Donor Liver Transplantation
Aims: We conducted this study to explore the interplay between VDR and CYP2R1 in liver graft and compared our findings with the pathological interpretation of serum 25(OH)D concentration.
Original paper ↗Read more →Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease
This study aimed at exploring the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and frailty or sarcopenia in 231 patients with CLD.
Original paper ↗Read more →Seasonal Variation in 25(OH)D at Aberdeen (57°N) and Bone Health Indicators: Could Holidays in the Sun and Cod Liver Oil Supplements Alleviate Deficiency?
The aim of this longitudinal study, was to assess predictors of seasonal variation of 25-hydroxy-vitamin D (25(OH)D) (including use of supplements and holidays in sunny destinations) at a northerly latitude in the UK (57°N) in relation to bone health indicators.
Original paper ↗Read more →Vitamin D and Liver Function
Explore how vitamin D and liver function interact through metabolism, insulin signalling, immune balance, and tissue regulation in a physiology-first framework.
Read more →Cellular degradation and feedback regulation of vitamin D: Study Summary
A concise study summary of how CYP24A1-mediated degradation and feedback mechanisms regulate vitamin D metabolites and local vitamin D activity.
Read more →Original sources
Read the full paper
Jones G, Prosser DE, Kaufmann M.
Publication details
Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research. 2014;55(1):13 to 31. Read the full paper.